{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:40:09Z","timestamp":1744180809821,"version":"3.40.3"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00103-019-03070-1","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T13:05:46Z","timestamp":1576069546000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Entwicklung von Impfstoffen gegen Malaria \u2013 aktueller Stand","Development of malaria vaccines\u2014state of the art"],"prefix":"10.1007","volume":"63","author":[{"given":"Wolfram Gottfried","family":"Metzger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita","family":"Sulyok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Theurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"key":"3070_CR1","first-page":"407","volume":"151","author":"E Sergent","year":"1910","unstructured":"Sergent\u00a0E, Sergent\u00a0E (1910) Sur l\u2019immunite sdans le paludismedes oiseaux. Conservation in vitro des sporozoites de plasmodium de Plasmodium relictum immmunite relative obtenue par inoculations de ces sporozoites. C\u00a0R Acad Sci 151:407\u2013409","journal-title":"C R Acad Sci"},{"issue":"5111","key":"3070_CR2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/216160a0","volume":"216","author":"RS Nussenzweig","year":"1967","unstructured":"Nussenzweig\u00a0RS, Vanderberg\u00a0J, Most\u00a0H, Orton\u00a0C (1967) Protective immunity produced by the injection of x\u2011irradiated sporozoites of plasmodium berghei. Nature 216(5111):160\u2013162","journal-title":"Nature"},{"issue":"3","key":"3070_CR3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00000441-197309000-00002","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde\u00a0DF, Most\u00a0H, McCarthy\u00a0VC, Vanderberg\u00a0JP (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266(3):169\u2013177","journal-title":"Am J Med Sci"},{"issue":"4706","key":"3070_CR4","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala\u00a0F, Tam\u00a0JP, Hollingdale\u00a0MR et\u00a0al (1985) Rationale for development of a\u00a0synthetic vaccine against Plasmodium falciparum malaria. Science 228(4706):1436\u20131440","journal-title":"Science"},{"key":"3070_CR5","volume-title":"United States Patent Patent Number: 4,466,917 Date of Patent Aug. 21","author":"RS Nussenzweig","year":"1984","unstructured":"Nussenzweig\u00a0RS, Godson\u00a0GN, Nussenzweig\u00a0V (1984) United States Patent Patent Number: 4,466,917 Date of Patent Aug. 21"},{"key":"3070_CR6","unstructured":"Ballou WR, Cahill CP (2007) Two decades of commitment to malaria vaccine development: glaxosmithkline biologicals. American Society of Tropical Medicine and Hygiene. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1706\/. Zugegriffen: 1. Nov. 2019"},{"key":"3070_CR7","unstructured":"Brown P Scientist whose dream of beating disease came true (1999) The Guardian. https:\/\/www.theguardian.com\/uk\/1999\/jul\/24\/paulbrown. Zugegriffen: 1. Nov. 2019"},{"key":"3070_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005966","author":"P Graves","year":"2006","unstructured":"Graves\u00a0P, Gelband\u00a0H (2006) Vaccines for preventing malaria (SPf66). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005966","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"3070_CR9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1365-3024.1997.d01-171.x","volume":"19","author":"KA Bojang","year":"1997","unstructured":"Bojang\u00a0KA, Obaro\u00a0SK, Leach\u00a0A et al (1997) Follow-up of Gambian children recruited to a\u00a0pilot safety and immunogenicity study of the malaria vaccine SPf66. Parasite Immunol 19(12):579\u2013581","journal-title":"Parasite Immunol"},{"issue":"7","key":"3070_CR10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1365-3024.1999.00231.x","volume":"21","author":"WG Metzger","year":"1999","unstructured":"Metzger\u00a0WG, Haywood\u00a0M, D\u2019Alessandro\u00a0U et\u00a0al (1999) Serological responses of Gambian children to immunization with the malaria vaccine SPf66. Parasite Immunol 21(7):335\u2013340","journal-title":"Parasite Immunol"},{"issue":"9906","key":"3070_CR11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(13)62238-2","volume":"382","author":"VS Moorthy","year":"2013","unstructured":"Moorthy\u00a0VS, Newman\u00a0RD, Okwo-Bele\u00a0J\u2011M (2013) Malaria vaccine technology roadmap. Lancet 382(9906):1700\u20131701","journal-title":"Lancet"},{"issue":"7182","key":"3070_CR12","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/4511042a","volume":"451","author":"B Maher","year":"2008","unstructured":"Maher\u00a0B (2008) Malaria: the end of the beginning. Nature 451(7182):1042\u20131046","journal-title":"Nature"},{"key":"3070_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-4939-9550-9_13","volume":"2013","author":"L von Seidlein","year":"2019","unstructured":"von Seidlein\u00a0L (2019) The advanced development pathway of the RTS,S\/AS01 vaccine. Methods Mol Biol 2013:177\u2013187","journal-title":"Methods Mol Biol"},{"issue":"10182","key":"3070_CR14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(19)30937-7","volume":"393","author":"P Adepoju","year":"2019","unstructured":"Adepoju\u00a0P (2019) RTS,S malaria vaccine pilots in three African countries. Lancet 393(10182):1685","journal-title":"Lancet"},{"key":"3070_CR15","unstructured":"Robert Koch-Institut (RKI) (2017) Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2017. www.rki.de\/jahrbuch. Zugegriffen: 1. Nov. 2019"},{"issue":"9","key":"3070_CR16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ebiom.2015.07.033","volume":"2","author":"A Lalremruata","year":"2015","unstructured":"Lalremruata\u00a0A, Magris\u00a0M, Vivas-Mart\u00ednez\u00a0S et al (2015) Natural infection of Plasmodium brasilianum in humans: man and monkey share quartan malaria parasites in the Venezuelan Amazon. EBioMedicine 2(9):1186\u20131192","journal-title":"EBioMedicine"},{"key":"3070_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13320","author":"WG Metzger","year":"2020","unstructured":"Metzger\u00a0WG, Ehni\u00a0H\u2011J, Kremsner\u00a0PG, Mordmueller\u00a0BG (2020) Experimental infections in humans\u2014historical and ethical reflections. Trop Med Int Health. https:\/\/doi.org\/10.1111\/tmi.13320","journal-title":"Trop Med Int Health"},{"issue":"7642","key":"3070_CR18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller\u00a0B, Surat\u00a0G, Lagler\u00a0H et\u00a0al (2017) Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542(7642):445\u2013449","journal-title":"Nature"},{"key":"3070_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz030","author":"O M\u00fcller","year":"2019","unstructured":"M\u00fcller\u00a0O, Lu\u00a0GY, von Seidlein\u00a0L (2019) Geographic expansion of artemisinin resistance. J\u00a0Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taz030","journal-title":"J Travel Med"},{"key":"3070_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12936-016-1239-0","volume":"15","author":"M Romay-Barja","year":"2016","unstructured":"Romay-Barja\u00a0M, Cano\u00a0J, Ncogo\u00a0P et al (2016) Determinants of delay in malaria care-seeking behaviour for children 15 years and under in Bata district, Equatorial Guinea. Malar\u00a0J 15:187","journal-title":"Malar J"},{"issue":"10","key":"3070_CR21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1365-3156.2005.01476.x","volume":"10","author":"E Worrall","year":"2005","unstructured":"Worrall\u00a0E, Basu\u00a0S, Hanson\u00a0K (2005) Is malaria a\u00a0disease of poverty? A review of the literature. Trop Med Int Health 10(10):1047\u20131059","journal-title":"Trop Med Int Health"},{"issue":"3","key":"3070_CR22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/a-0916-5128","volume":"26","author":"C Rothe","year":"2019","unstructured":"Rothe\u00a0C, Boecken\u00a0G, Rosenbusch\u00a0D et\u00a0al (2019) Empfehlungen zur Malariaprophylaxe. Flug Reisemed 26(3):105\u2013132","journal-title":"Flug Reisemed"},{"issue":"2","key":"3070_CR23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4269\/ajtmh.1994.51.123","volume":"51","author":"JF Trape","year":"1994","unstructured":"Trape\u00a0JF, Rogier\u00a0C, Konate\u00a0L et\u00a0al (1994) The Dielmo project: a\u00a0longitudinal study of natural malaria infection and the mechanisms of protective immunity in a\u00a0community living in a\u00a0holoendemic area of Senegal. Am J Trop Med Hyg 51(2):123\u2013137","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"3070_CR24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ni.f.205","volume":"9","author":"J Langhorne","year":"2008","unstructured":"Langhorne\u00a0J, Ndungu\u00a0FM, Sponaas\u00a0A\u2011M, Marsh\u00a0K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9(7):725\u2013732","journal-title":"Nat Immunol"},{"key":"3070_CR25","unstructured":"WHO Tables of malaria vaccine projects globally. WHO. http:\/\/www.who.int\/immunization\/research\/development\/Rainbow_tables\/en\/. Zugegriffen: 11. Aug. 2019"},{"issue":"11","key":"3070_CR26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn\u00a0IA, Seder\u00a0RA (2018) Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat Immunol 19(11):1199\u20131211","journal-title":"Nat Immunol"},{"key":"3070_CR27","unstructured":"WHO Malaria vaccines. http:\/\/www.who.int\/immunization\/research\/development\/malaria\/en\/. Zugegriffen: 31. Juli 2019"},{"issue":"2","key":"3070_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14760584.2019.1561289","volume":"18","author":"KL Wilson","year":"2019","unstructured":"Wilson\u00a0KL, Flanagan\u00a0KL, Prakash\u00a0MD, Plebanski\u00a0M (2019) Malaria vaccines in the eradication era: current status and future perspectives. Expert Rev Vaccines 18(2):133\u2013151","journal-title":"Expert Rev Vaccines"},{"issue":"4702","key":"3070_CR29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.2988126","volume":"228","author":"WR Ballou","year":"1985","unstructured":"Ballou\u00a0WR, Rothbard\u00a0J, Wirtz\u00a0RA et\u00a0al (1985) Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 228(4702):996\u2013999","journal-title":"Science"},{"issue":"42\u201343","key":"3070_CR30","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2006.06.033","volume":"24","author":"VA Stewart","year":"2006","unstructured":"Stewart\u00a0VA, McGrath\u00a0SM, Walsh\u00a0DS et al (2006) Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S\/AS02A. Vaccine 24(42\u201343):6483\u20136492","journal-title":"Vaccine"},{"issue":"7","key":"3070_CR31","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"RTS,S Clinical Trials Partnership","year":"2014","unstructured":"RTS,S Clinical Trials Partnership (2014) Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18\u00a0months after vaccination: a\u00a0phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11(7):e1001685","journal-title":"PLoS Med"},{"issue":"9988","key":"3070_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a\u00a0booster dose in infants and children in Africa: final results of a\u00a0phase 3, individually randomised, controlled trial. Lancet 386(9988):31\u201345","journal-title":"Lancet"},{"issue":"10005","key":"3070_CR33","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(15)00694-7","volume":"386","author":"O M\u00fcller","year":"2015","unstructured":"M\u00fcller\u00a0O, Tozan\u00a0Y, Becher\u00a0H (2015) RTS,S\/AS01 malaria vaccine and child mortality. Lancet 386(10005):1736","journal-title":"Lancet"},{"issue":"10005","key":"3070_CR34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0140-6736(15)00693-5","volume":"386","author":"P Aaby","year":"2015","unstructured":"Aaby\u00a0P, Rodrigues\u00a0A, Kofoed\u00a0P\u2011E, Benn\u00a0CS (2015) RTS,S\/AS01 malaria vaccine and child mortality. Lancet 386(10005):1735\u20131736","journal-title":"Lancet"},{"issue":"2","key":"3070_CR35","doi-asserted-by":"crossref","first-page":"e00514","DOI":"10.1128\/mBio.00514-16","volume":"7","author":"SL Klein","year":"2016","unstructured":"Klein\u00a0SL, Shann\u00a0F, Moss\u00a0WJ, Benn\u00a0CS, Aaby\u00a0P (2016) RTS,S Malaria Vaccine and Increased Mortality in Girls. mBio 7(2):e514\u2013e516","journal-title":"mBio"},{"key":"3070_CR36","unstructured":"European Medicines Agency (2018) Mosquirix H\u2011W-2300. https:\/\/www.ema.europa.eu\/en\/mosquirix-h-w-2300. Zugegriffen: 1. Nov. 2019"},{"key":"3070_CR37","unstructured":"Mesa (2019) Large-scale implementation of the RTS,S malaria vaccine: phase IV trial. https:\/\/mesamalaria.org\/mesa-track\/large-scale-implementation-rtss-malaria-vaccine-phase-iv-trial. Zugegriffen: 1. Nov. 2019"},{"key":"3070_CR38","doi-asserted-by":"crossref","unstructured":"Butler D (2019) Promising malaria vaccine to be tested in first large field trial. Nature. http:\/\/www.nature.com\/articles\/d41586-019-01232-4. Zugegriffen: 1. Nov. 2019","DOI":"10.1038\/d41586-019-01232-4"},{"issue":"38","key":"3070_CR39","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2008.07.017","volume":"26","author":"LA Purcell","year":"2008","unstructured":"Purcell\u00a0LA, Wong\u00a0KA, Yanow\u00a0SK, Lee\u00a0M, Spithill\u00a0TW, Rodriguez\u00a0A (2008) Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge. Vaccine 26(38):4880\u20134884","journal-title":"Vaccine"},{"issue":"7022","key":"3070_CR40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nature03188","volume":"433","author":"A-K Mueller","year":"2005","unstructured":"Mueller\u00a0A\u2011K, Labaied\u00a0M, Kappe\u00a0SHI, Matuschewski\u00a0K (2005) Genetically modified Plasmodium parasites as a\u00a0protective experimental malaria vaccine. Nature 433(7022):164\u2013167","journal-title":"Nature"},{"issue":"43","key":"3070_CR41","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2013.08.007","volume":"31","author":"M Spring","year":"2013","unstructured":"Spring\u00a0M, Murphy\u00a0J, Nielsen\u00a0R et al (2013) First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31(43):4975\u20134983","journal-title":"Vaccine"},{"issue":"9","key":"3070_CR42","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/mt.2014.85","volume":"22","author":"SA Mikolajczak","year":"2014","unstructured":"Mikolajczak\u00a0SA, Lakshmanan\u00a0V, Fishbaugher\u00a0M et al (2014) A next-generation genetically attenuated plasmodium falciparum parasite created by triple gene deletion. Mol Ther 22(9):1707\u20131715","journal-title":"Mol Ther"},{"key":"3070_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9099","author":"JG Kublin","year":"2017","unstructured":"Kublin\u00a0JG, Mikolajczak\u00a0SA, Sack\u00a0BK et\u00a0al (2017) Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aad9099","journal-title":"Sci Transl Med"},{"key":"3070_CR44","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3389\/fimmu.2019.01227","volume":"10","author":"YS Goh","year":"2019","unstructured":"Goh\u00a0YS, McGuire\u00a0D, R\u00e9nia\u00a0L (2019) Vaccination With Sporozoites: Models and Correlates of Protection. Front Immunol 10:1227","journal-title":"Front Immunol"},{"issue":"6","key":"3070_CR45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka\u00a0AS, Lyke\u00a0KE, DeZure\u00a0A et\u00a0al (2016) Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22(6):614\u2013623","journal-title":"Nat Med"},{"key":"3070_CR46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/978-1-62703-026-7_39","volume":"923","author":"L R\u00e9nia","year":"2013","unstructured":"R\u00e9nia\u00a0L, Gr\u00fcner\u00a0AC, Mauduit\u00a0M, Snounou\u00a0G (2013) Vaccination using normal live sporozoites under drug treatment. Methods Mol Biol 923:567\u2013576","journal-title":"Methods Mol Biol"},{"issue":"5","key":"3070_CR47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa0805832","volume":"361","author":"M Roestenberg","year":"2009","unstructured":"Roestenberg\u00a0M, McCall\u00a0M, Hopman\u00a0J et\u00a0al (2009) Protection against a\u00a0malaria challenge by sporozoite inoculation. N\u00a0Engl J Med 361(5):468\u2013477","journal-title":"N Engl J Med"},{"issue":"9779","key":"3070_CR48","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0140-6736(11)60360-7","volume":"377","author":"M Roestenberg","year":"2011","unstructured":"Roestenberg\u00a0M, Teirlinck\u00a0AC, McCall\u00a0MBB et al (2011) Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377(9779):1770\u20131776","journal-title":"Lancet"},{"issue":"19","key":"3070_CR49","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1073\/pnas.1220360110","volume":"110","author":"EM Bijker","year":"2013","unstructured":"Bijker\u00a0EM, Bastiaens\u00a0GJH, Teirlinck\u00a0AC (2013) Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 110(19):7862\u20137867","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6055","key":"3070_CR50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein\u00a0JE, Tewari\u00a0K, Lyke\u00a0KE et\u00a0al (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334(6055):475\u2013480","journal-title":"Science"},{"issue":"1","key":"3070_CR51","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein\u00a0JE, Paolino\u00a0KM, Richie\u00a0TL et\u00a0al (2017) Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2(1):e89154","journal-title":"JCI Insight"},{"issue":"10","key":"3070_CR52","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke\u00a0KE, Ishizuka\u00a0AS, Berry\u00a0AA et al (2017) Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA 114(10):2711\u20132716","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3070_CR53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko\u00a0MS, Healy\u00a0SA, Katile\u00a0A (2017) Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a\u00a0randomised, double-blind phase 1 trial. Lancet Infect Dis 17(5):498\u2013509","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"3070_CR54","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu\u00a0A, Urbano\u00a0V, Hamad\u00a0A et al (2018) Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, Tolerability, and Immunogenicity of pfSPZ vaccine for malaria in healthy Equatoguinean men. Am J Trop Med Hyg 98(1):308\u2013318","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"3070_CR55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/femsre\/fuw001","volume":"40","author":"JG Beeson","year":"2016","unstructured":"Beeson\u00a0JG, Drew\u00a0DR, Boyle\u00a0MJ, Feng\u00a0G, Fowkes\u00a0FJI, Richards\u00a0JS (2016) Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. FEMS Microbiol Rev 40(3):343\u2013372","journal-title":"FEMS Microbiol Rev."},{"issue":"6","key":"3070_CR56","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","volume":"185","author":"B Genton","year":"2002","unstructured":"Genton\u00a0B, Betuela\u00a0I, Felger\u00a0I et al (2002) A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a\u00a0phase 1\u20112b trial in Papua New Guinea. J\u00a0INFECT DIS 185(6):820\u2013827","journal-title":"J INFECT DIS"},{"issue":"3","key":"3070_CR57","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1371\/journal.pone.0004708","volume":"4","author":"BR Ogutu","year":"2009","unstructured":"Ogutu\u00a0BR, Apollo\u00a0OJ, McKinney\u00a0D et al (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 4(3):e4708","journal-title":"PLoS ONE"},{"issue":"38","key":"3070_CR58","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","volume":"34","author":"SB Sirima","year":"2016","unstructured":"Sirima\u00a0SB, Mordm\u00fcller\u00a0B, Milligan\u00a0P et\u00a0al (2016) A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine 34(38):4536\u20134542","journal-title":"Vaccine"},{"key":"3070_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1087","author":"JC Dejon-Agobe","year":"2018","unstructured":"Dejon-Agobe\u00a0JC, Ateba-Ngoa\u00a0U, Lalremruata\u00a0A et al (2018) Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciy1087","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3070_CR60","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/14760584.2017.1355246","volume":"16","author":"M Theisen","year":"2017","unstructured":"Theisen\u00a0M, Adu\u00a0B, Mordm\u00fcller\u00a0B, Singh\u00a0S (2017) The GMZ2 malaria vaccine: from concept to efficacy in humans. Expert Rev Vaccines 16(9):907\u2013917","journal-title":"Expert Rev Vaccines"},{"key":"3070_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00155-17","author":"A J\u00e4schke","year":"2017","unstructured":"J\u00e4schke\u00a0A, Coulibaly\u00a0B, Remarque\u00a0EJ, Bujard\u00a0H, Epp\u00a0C (2017) Merozoite surface protein 1 from plasmodium falciparum is a\u00a0major target of opsonizing antibodies in individuals with acquired immunity against malaria. Clin Vaccine Immunol. https:\/\/doi.org\/10.1128\/CVI.00155-17","journal-title":"Clin Vaccine Immunol"},{"key":"3070_CR62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96381","author":"RO Payne","year":"2019","unstructured":"Payne\u00a0RO, Silk\u00a0SE, Elias\u00a0SC et\u00a0al (2019) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.96381","journal-title":"JCI Insight"},{"key":"3070_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23194-9","author":"T Tougan","year":"2018","unstructured":"Tougan\u00a0T, Edula\u00a0JR, Takashima\u00a0E et\u00a0al (2018) Molecular camouflage of plasmodium falciparum merozoites by binding of host vitronectin to P47 fragment of SERA5. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-23194-9","journal-title":"Sci Rep"},{"issue":"9333","key":"3070_CR64","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(02)09784-2","volume":"360","author":"DJ Pombo","year":"2002","unstructured":"Pombo\u00a0DJ, Lawrence\u00a0G, Hirunpetcharat\u00a0C et al (2002) Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360(9333):610\u2013617","journal-title":"Lancet"},{"issue":"1","key":"3070_CR65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12916-018-1173-9","volume":"16","author":"DI Stanisic","year":"2018","unstructured":"Stanisic\u00a0DI, Fink\u00a0J, Mayer\u00a0J et al (2018) Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-na\u00efve volunteers: a\u00a0pilot study. BMC Med 16(1):184","journal-title":"BMC Med"},{"issue":"7","key":"3070_CR66","doi-asserted-by":"crossref","first-page":"e0131456","DOI":"10.1371\/journal.pone.0131456","volume":"10","author":"A Boes","year":"2015","unstructured":"Boes\u00a0A, Spiegel\u00a0H, Voepel\u00a0N et al (2015) Analysis of a\u00a0multi-component multi-stage malaria vaccine candidate\u2014tackling the cocktail challenge. PLoS ONE 10(7):e131456","journal-title":"PLoS ONE"},{"key":"3070_CR67","unstructured":"Multi-Stage Malaria Vaccine Consortium: field efficacy testing of a\u00a0malaria vaccine targeting all four stages of the parasite\u2019s life-cycle\u2014ERA-LEARN. https:\/\/www.era-learn.eu\/network-information\/networks\/edctp-ii\/vaccines-for-poverty-related-diseases-prds\/multi-stage-malaria-vaccine-consortium-field-efficacy-testing-of-a-malaria-vaccine-targeting-all-four-stages-of-the-parasites-life-cycle. Zugegriffen: 12. August 2019"},{"issue":"6","key":"3070_CR68","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14760584.2017.1322512","volume":"16","author":"C Pehrson","year":"2017","unstructured":"Pehrson\u00a0C, Salanti\u00a0A, Theander\u00a0TG, Nielsen\u00a0MA (2017) Pre-clinical and clinical development of the first placental malaria vaccine. Expert Rev Vaccines 16(6):613\u2013624","journal-title":"Expert Rev Vaccines"},{"key":"3070_CR69","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025551","author":"M Fried","year":"2017","unstructured":"Fried\u00a0M, Duffy\u00a0PE (2017) Malaria during pregnancy. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a025551","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"52","key":"3070_CR70","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1016\/j.vaccine.2015.10.011","volume":"33","author":"M Fried","year":"2015","unstructured":"Fried\u00a0M, Duffy\u00a0PE (2015) Designing a\u00a0VAR2CSA-based vaccine to prevent placental malaria. Vaccine 33(52):7483\u20137488","journal-title":"Vaccine"},{"issue":"27","key":"3070_CR71","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1016\/j.vaccine.2017.05.027","volume":"35","author":"K Gb\u00e9dand\u00e9","year":"2017","unstructured":"Gb\u00e9dand\u00e9\u00a0K, Fievet\u00a0N, Viwami\u00a0F et al (2017) Clinical development of a\u00a0VAR2CSA-based placental malaria vaccine PAMVAC: quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae. Vaccine 35(27):3474\u20133481","journal-title":"Vaccine"},{"key":"3070_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1140","author":"B Mordm\u00fcller","year":"2019","unstructured":"Mordm\u00fcller\u00a0B, Sulyok\u00a0M, Egger-Adam\u00a0D et al (2019) First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a\u00a0vaccine candidate to prevent pregnancy-associated malaria. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciy1140","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3070_CR73","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4161\/hv.22129","volume":"8","author":"TL Richie","year":"2012","unstructured":"Richie\u00a0TL, Charoenvit\u00a0Y, Wang\u00a0R et al (2012) Clinical trial in healthy malaria-na\u00efve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a\u00a0five-gene, sporozoite\/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother 8(11):1564\u20131584","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3070_CR74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-3156.2008.02194.x","volume":"14","author":"WP O\u2019Meara","year":"2009","unstructured":"O\u2019Meara\u00a0WP, Noor\u00a0A, Gatakaa\u00a0H, Tsofa\u00a0B, McKenzie\u00a0FE, Marsh\u00a0K (2009) The impact of primary health care on malaria morbidity\u2014defining access by disease burden. Trop Med Int Health 14(1):29\u201335","journal-title":"Trop Med Int Health"},{"key":"3070_CR75","unstructured":"Bundesregierung In die Zukunft investieren: Malaria besiegen. https:\/\/www.bundesregierung.de\/breg-de\/aktuelles\/in-die-zukunft-investieren-malaria-besiegen-438820. Zugegriffen: 5. Aug. 2019"},{"key":"3070_CR76","unstructured":"Gr\u00f6he H Gemeinsame Verantwortung der G20-Partnerl\u00e4nder f\u00fcr die globale Gesundheit\u201c. Bundesgesundheitsministerium. https:\/\/www.bundesgesundheitsministerium.de\/presse\/pressemitteilungen\/2016\/4-quartal\/g20-praesidentschaft.html. Zugegriffen: 6. Aug. 2019"},{"key":"3070_CR77","volume-title":"Globale Gesundheitspolitik gestalten, gemeinsam handeln, Verantwortung wahrnehmen: Konzept der Bundesregierung","author":"Bundesregierung","year":"2013","unstructured":"Bundesregierung (2013) Globale Gesundheitspolitik gestalten, gemeinsam handeln, Verantwortung wahrnehmen: Konzept der Bundesregierung. Publikationsversand der Bundesregierung, Rostock"},{"issue":"10097","key":"3070_CR78","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(17)31460-5","volume":"390","author":"I Kickbusch","year":"2017","unstructured":"Kickbusch\u00a0I, Franz\u00a0C, Holzscheiter\u00a0A et\u00a0al (2017) Germany\u2019s expanding role in global health. Lancet 390(10097):898\u2013912","journal-title":"Lancet"},{"key":"3070_CR79","unstructured":"BMZ (2019) Marshallplan mit Afrika. http:\/\/www.bmz.de\/de\/laender_regionen\/marshallplan_mit_afrika\/index.html. Zugegriffen: 6. Aug. 2019"},{"key":"3070_CR80","volume-title":"Erkl\u00e4rung des Internationalen Beratergremiums zu globaler Gesundheit","author":"IAB","year":"2019","unstructured":"IAB (2019) Erkl\u00e4rung des Internationalen Beratergremiums zu globaler Gesundheit"},{"key":"3070_CR81","unstructured":"Global Fund (2019) Global fund overview. https:\/\/www.theglobalfund.org\/en\/overview\/. Zugegriffen: 7. Aug. 2019"},{"key":"3070_CR82","unstructured":"BMZ (2019) Globaler Fonds zur Bek\u00e4mpfung von Aids, Tuberkulose und Malaria. http:\/\/www.bmz.de\/de\/ministerium\/wege\/multilaterale_ez\/akteure\/wio\/gfatm\/index.html. Zugegriffen: 7. Aug. 2019"},{"key":"3070_CR83","unstructured":"BMZ (2018) Entwicklungsminister M\u00fcller sagt neue Unterst\u00fctzung im Kampf gegen Aids zu. http:\/\/www.bmz.de\/de\/presse\/aktuelleMeldungen\/2018\/november\/181130_Entwicklungsminister-Mueller-sagt-neue-Unterstuetzung-im-Kampf-gegen-AIDS-zu\/index.html. Zugegriffen: 7. Aug. 2019"},{"key":"3070_CR84","unstructured":"Deutscher Bundestag (2017) Bericht des Ausschusses f\u00fcr Bildung, Forschung und Technikfolgenabsch\u00e4tzung (18. Ausschuss) gem\u00e4\u00df \u00a7 56a der Gesch\u00e4ftsordnung Technikfolgenabsch\u00e4tzung (TA) Neue Arzneimittel gegen vernachl\u00e4ssigte Krankheiten Endbericht zum TA-Projekt \u201eMedikamente f\u00fcr Afrika\u201c.http:\/\/dip21.bundestag.de\/dip21\/btd\/18\/123\/1812306.pdf. Zugegriffen: 7. August 2019"},{"issue":"25","key":"3070_CR85","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1016\/j.vaccine.2016.10.047","volume":"36","author":"WHO","year":"2018","unstructured":"WHO (2018) Malaria vaccine: WHO position paper, January 2016\u2014Recommendations. Vaccine 36(25):3576\u20133577","journal-title":"Vaccine"},{"key":"3070_CR86","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID, WHO (1988) Smallpox and its eradication. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/39485. Zugegriffen: 22. Juni 2019"},{"issue":"3","key":"3070_CR87","first-page":"14","volume":"49","author":"D Baxby","year":"1999","unstructured":"Baxby\u00a0D (1999) The end of smallpox. Hist Today 49(3):14\u201316","journal-title":"Hist Today"},{"key":"3070_CR88","volume-title":"Smallpox: the death of a\u00a0disease. The inside story of eradicating a\u00a0world wide killer","author":"DA Henderson","year":"2009","unstructured":"Henderson\u00a0DA (2009) Smallpox: the death of a\u00a0disease. The inside story of eradicating a\u00a0world wide killer, 1.\u00a0Aufl. Prometheus Books, Amherst, New York","edition":"1"},{"issue":"12","key":"3070_CR89","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0141076815605211","volume":"108","author":"WG Metzger","year":"2015","unstructured":"Metzger\u00a0WG, K\u00f6hler\u00a0C, Mordm\u00fcller\u00a0B (2015) Lessons from a\u00a0modern review of the smallpox eradication files. J\u00a0R Soc Med 108(12):473\u2013477","journal-title":"J R Soc Med"},{"issue":"10","key":"3070_CR90","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/trstmh\/trw073","volume":"110","author":"P Aaby","year":"2016","unstructured":"Aaby\u00a0P, Ravn\u00a0H, Fisker\u00a0AB, Rodrigues\u00a0A, Benn\u00a0CS (2016) Is diphtheria-tetanus-pertussis (DTP) associated with increased female mortality? A meta-analysis testing the hypotheses of sex-differential non-specific effects of DTP vaccine. Trans R Soc Trop Med Hyg 110(10):570\u2013581","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9","key":"3070_CR91","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/trstmh\/trw059","volume":"110","author":"P Aaby","year":"2016","unstructured":"Aaby\u00a0P, Nielsen\u00a0J, Benn\u00a0CS, Trape\u00a0J\u2011F (2016) Sex-differential effects on mortality of BCG and diphtheria-tetanus-pertussis vaccines in a\u00a0rural area with high vaccination coverage: observational study from Senegal. Trans R Soc Trop Med Hyg 110(9):527\u2013533","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"26","key":"3070_CR92","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu\u00a0A, Fegan\u00a0G, Wambua\u00a0J (2016) Seven-year efficacy of RTS,S\/AS01 malaria vaccine among young African children. N\u00a0Engl J Med 374(26):2519\u20132529","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3070_CR93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0035-9203(99)90330-9","volume":"93","author":"M Haywood","year":"1999","unstructured":"Haywood\u00a0M, Conway\u00a0DJ, Weiss\u00a0H et\u00a0al (1999) Reduction in the mean number of plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66. Trans R Soc Trop Med Hyg 93(Suppl 1):65\u201368","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3070_CR94","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3389\/fimmu.2018.01397","volume":"9","author":"S Ratto-Kim","year":"2018","unstructured":"Ratto-Kim\u00a0S, Yoon\u00a0I\u2011K, Paris\u00a0RM, Excler\u00a0J\u2011L, Kim\u00a0JH, O\u2019Connell\u00a0RJ (2018) The US military commitment to vaccine development: a century of successes and challenges. Front Immunol 9:1397","journal-title":"Front Immunol"},{"key":"3070_CR95","unstructured":"EDCTP (2019) Malaria portfolio: large investments in treatment and vaccines. EDCTP. http:\/\/www.edctp.org\/news\/edctp-malaria-portfolio-large-investments-in-treatment-and-vaccine\/. Zugegriffen: 12. Aug. 2019"},{"key":"3070_CR96","unstructured":"CureVac (2019) CureVac entwickelt innovative mRNA-Impfstoffe gegen Influenza und Malaria. https:\/\/www.curevac.com\/de\/newsroom\/news\/curevac-entwickelt-innovative-mrna-impfstoffe-gegen-influenza-und-malaria\/. Zugegriffen: 12. Aug. 2019"},{"key":"3070_CR97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/d41586-019-01342-z","volume":"569","author":"A Maxmen","year":"2019","unstructured":"Maxmen\u00a0A (2019) First proven malaria vaccine rolled out in Africa\u2014but doubts linger. Nature 569:14\u201315","journal-title":"Nature"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-019-03070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-019-03070-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-019-03070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:06:40Z","timestamp":1744178800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-019-03070-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,11]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["3070"],"URL":"https:\/\/doi.org\/10.1007\/s00103-019-03070-1","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"type":"print","value":"1436-9990"},{"type":"electronic","value":"1437-1588"}],"subject":[],"published":{"date-parts":[[2019,12,11]]},"assertion":[{"value":"11 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"W.\u00a0Metzger, Z.\u00a0Sulyok, A.\u00a0Theurer und C.\u00a0K\u00f6hler geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Bei der Abfassung dieser Arbeit wurden alle ethischen Richtlinien eingehalten.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}